Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
RESEARCH TOOLSreports
Iterum Therapeutics (ITRM) Stock Price & Analysis
700 Followers
ITRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.62 - $2.50
Previous Close$1.29
Volume60.24K
Average Volume (3M)157.96K
Market Cap
$21.02M
Enterprise Value$15.34M
Total Cash (Recent Filing)$18.21M
Total Debt (Recent Filing)$12.20M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 09, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding16,554,885
10 Day Avg. Volume99,866
30 Day Avg. Volume157,960
Standard Deviation0.39
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-3.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$6.50Price Target Upside411.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Iterum Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Development & ApprovalIterum is advancing sulopenem, a potential first-in-class antibiotic for urinary tract infections, with a strong efficacy profile demonstrated in Phase 3 trials.
Financial StabilityWith a cash runway extending into 2025, Iterum is well-positioned to continue its operations and focus on the FDA approval process for sulopenem without financial constraints.
Strategic Business DecisionsIterum Therapeutics is exploring strategic options such as selling or licensing sulopenem, which could significantly enhance shareholder value upon successful commercialization.
Bears Say
The company reported a net loss for the fourth quarter, which could raise concerns about its long-term profitability.
Clinical Trial OutcomesPrior P3 data missed on non-inferiority in the cipro-susceptible population and was only superior in the non-susceptible population.
Regulatory ChallengesKey risks include failure to secure FDA approval, potentially impacting the stock's future performance.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITRM FAQ
What was Iterum Therapeutics Plc’s price range in the past 12 months?
Iterum Therapeutics Plc lowest stock price was $0.62 and its highest was $2.50 in the past 12 months.
What is Iterum Therapeutics Plc’s market cap?
Currently, no data Available
When is Iterum Therapeutics Plc’s upcoming earnings report date?
Iterum Therapeutics Plc’s upcoming earnings report date is Aug 09, 2024 which is in 71 days.
How were Iterum Therapeutics Plc’s earnings last quarter?
Iterum Therapeutics Plc released its earnings results on May 13, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.725 by $0.345.
Is Iterum Therapeutics Plc overvalued?
According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Undervalued.
Does Iterum Therapeutics Plc pay dividends?
Iterum Therapeutics Plc does not currently pay dividends.
What is Iterum Therapeutics Plc’s EPS estimate?
Iterum Therapeutics Plc’s EPS estimate is -$0.44.
How many shares outstanding does Iterum Therapeutics Plc have?
Iterum Therapeutics Plc has 16,554,886 shares outstanding.
What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?
Iterum Therapeutics Plc reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.725. Following the earnings report the stock price went down -1.935%.
Which hedge fund is a major shareholder of Iterum Therapeutics Plc?
Among the largest hedge funds holding Iterum Therapeutics Plc’s share is New Leaf Venture Partners, L.L.C.. It holds Iterum Therapeutics Plc’s shares valued at 150K.
---
Iterum Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (411.81% Upside)
$6.50 (411.81% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.65%
12-Months-Change
Fundamentals
Return on Equity
-555.68%
Trailing 12-Months
Asset Growth
-66.23%
Trailing 12-Months
Company Description
Iterum Therapeutics Plc
Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
---
ITRM Stock 12 Month Forecast
Average Price Target
$6.50
▲(411.81% Upside)
Technical Analysis
Summit Therapeutics
―
Mersana Therapeutics
―
Apellis Pharmaceuticals
―
Eton Pharmaceuticals
―
Best Analysts Covering ITRM
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-34.77%
reiterated a buy rating 17 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.77% per trade.
---